Théo bourgeron (54 Ergebnisse)

Paperback. Zustand: New. Powerful financial forces have supported the neoliberal project since the 1980s to advance their interests; but there are now signs that these forces have a new face and a new strategy. The majority of the British finance sector threw its support behind Britain leaving the European Union, a flagship institution of neoliberalism. Beyond this counterintuitive move, what was really happening and why? Alt-Finance examines a new authoritarian turn in financialised democracies, focusing on the City of London, revealing a dangerous alternative political project in the making. In a clash with traditional finance, the new behemoths of financial capital - hedge funds, private equity firms and real estate funds - have started to cohere around a set of political beliefs, promoting libertarian, authoritarian, climate-denying and Eurosceptic views. Protecting investments, supressing social dissent and reducing state interference are at the core of their mission for a new world order. By following the money, the authors provide indisputable evidence of these worrying developments. Through a clear analysis of the international dealings of this new authoritarian-libertarian regime, not just in Britain but in the US and Brazil, we can understand how our world is being shaped against our will by struggles between dominant groups.…

Zustand: new.

Paperback. Zustand: Brand New. 176 pages. 7.80x5.10x0.60 inches. In Stock.

Zustand: New.

Zustand: good. Befriedigend/Good: Durchschnittlich erhaltenes Buch bzw. Schutzumschlag mit Gebrauchsspuren, aber vollständigen Seiten. / Describes the average WORN book or dust jacket that has all the pages present.

Zustand: New. In English.

Zustand: very good. Gut/Very good: Buch bzw. Schutzumschlag mit wenigen Gebrauchsspuren an Einband, Schutzumschlag oder Seiten. / Describes a book or dust jacket that does show some signs of wear on either the binding, dust jacket or pages.

Zustand: New.

Zustand: As New. Unread book in perfect condition.

Zustand: new.

Paperback. Zustand: New. This book argues that we have reached the 'peak' of a particular model for pharmaceutical production - the neoliberal value model that has been in place since the early 1980s. 'Peak' designates a state where a value model's contradictions become exacerbated to a point where the system cannot but change: it is a point where an industry's products become too expensive and its resources exhausted, and where the coalitions that have held up that particular value model disintegrate. In other words, it is the point where an industry collapses under its own greed, of having captured too much value for itself, leaving too little to the other actors in the system.Peak Pharma argues that the neoliberal pharmaceutical system is reaching its 'peak' in several vital respects - peak pricing, peak concentration, peak financialization, and peak expansion. It uses the term to signal the crisis and possible end of an era-defining business model in the pharmaceutical sector. The book presents a synthesis of the authors' decade-long empirical investigations into social movements contesting the pharmaceutical market. It brings together a large body of knowledge that is currently spread across political economy, sociology, STS, organization studies, and the history of medicine, to follow the neoliberal dynamics that have engendered an acceleration toward 'peak' over the span of the last 40 years. It traces the emergence of different voices and groups that have contested this evolution, particularly around specific crisis points and revelatory moments, including the fight for access to HIV/AIDS medicines, the global health era, pharmaceutical corporate social responsibility, the advent of personalized medicine and digital health, Covid-19, and others. The authors trace the shifting coalitions between the pharmaceutical industry, patient organisations, and governments that kept propping up the neoliberal value system throughout this evolution. They show that the recent acceleration toward peak has led many centrist voices from patient organizations, academia and politics to start changing course from market repair to imagining alternative pharmaceutical economies, prominently including imaginaries around the pharmaceutical commons. The book closes with a set of recommendations for policy makers and civil society actors interested in fostering an alternative political economy of health.This is an open access title available under the terms of a [CC BY-NC-ND 4.0 International] licence. It is free to read at Oxford Scholarship Online and offered as a free PDF download from OUP and selected open access locations.…

Paperback. Zustand: New. This book argues that we have reached the 'peak' of a particular model for pharmaceutical production - the neoliberal value model that has been in place since the early 1980s. 'Peak' designates a state where a value model's contradictions become exacerbated to a point where the system cannot but change: it is a point where an industry's products become too expensive and its resources exhausted, and where the coalitions that have held up that particular value model disintegrate. In other words, it is the point where an industry collapses under its own greed, of having captured too much value for itself, leaving too little to the other actors in the system.Peak Pharma argues that the neoliberal pharmaceutical system is reaching its 'peak' in several vital respects - peak pricing, peak concentration, peak financialization, and peak expansion. It uses the term to signal the crisis and possible end of an era-defining business model in the pharmaceutical sector. The book presents a synthesis of the authors' decade-long empirical investigations into social movements contesting the pharmaceutical market. It brings together a large body of knowledge that is currently spread across political economy, sociology, STS, organization studies, and the history of medicine, to follow the neoliberal dynamics that have engendered an acceleration toward 'peak' over the span of the last 40 years. It traces the emergence of different voices and groups that have contested this evolution, particularly around specific crisis points and revelatory moments, including the fight for access to HIV/AIDS medicines, the global health era, pharmaceutical corporate social responsibility, the advent of personalized medicine and digital health, Covid-19, and others. The authors trace the shifting coalitions between the pharmaceutical industry, patient organisations, and governments that kept propping up the neoliberal value system throughout this evolution. They show that the recent acceleration toward peak has led many centrist voices from patient organizations, academia and politics to start changing course from market repair to imagining alternative pharmaceutical economies, prominently including imaginaries around the pharmaceutical commons. The book closes with a set of recommendations for policy makers and civil society actors interested in fostering an alternative political economy of health.This is an open access title available under the terms of a [CC BY-NC-ND 4.0 International] licence. It is free to read at Oxford Scholarship Online and offered as a free PDF download from OUP and selected open access locations.…

Paperback. Zustand: Brand New. In Stock.

Zustand: New.

Paperback. Zustand: New. Brand new book, sourced directly from publisher. Dispatch time is 7-8 days from our warehouse. Book will be sent in robust, secure packaging to ensure it reaches you securely.

Zustand: As New. Unread book in perfect condition.

Zustand: New.

ÉTAT : NEUF / NEW CONDITION 9782072985959 542725 17.

Zustand: New.

Paperback. Zustand: Brand New. 304 pages. 6.10x0.71x9.25 inches. In Stock.

Zustand: New. InhaltsverzeichnisIntroduction 1. The Big Money Behind Brexit 2. Second-Wave Finance vs. the European Union 3. From European Neoliberalism to Authoritarian Libertarianism Epilogue: The Drumbeat of WarList.

Zustand: New.

Zustand: As New. Unread book in perfect condition.

Zustand: NEW.

Paperback. Zustand: New. Powerful financial forces have supported the neoliberal project since the 1980s to advance their interests; but there are now signs that these forces have a new face and a new strategy. The majority of the British finance sector threw its support behind Britain leaving the European Union, a flagship institution of neoliberalism. Beyond this counterintuitive move, what was really happening and why? Alt-Finance examines a new authoritarian turn in financialised democracies, focusing on the City of London, revealing a dangerous alternative political project in the making. In a clash with traditional finance, the new behemoths of financial capital - hedge funds, private equity firms and real estate funds - have started to cohere around a set of political beliefs, promoting libertarian, authoritarian, climate-denying and Eurosceptic views. Protecting investments, supressing social dissent and reducing state interference are at the core of their mission for a new world order. By following the money, the authors provide indisputable evidence of these worrying developments. Through a clear analysis of the international dealings of this new authoritarian-libertarian regime, not just in Britain but in the US and Brazil, we can understand how our world is being shaped against our will by struggles between dominant groups.…

Paperback. Zustand: New. This book argues that we have reached the 'peak' of a particular model for pharmaceutical production - the neoliberal value model that has been in place since the early 1980s. 'Peak' designates a state where a value model's contradictions become exacerbated to a point where the system cannot but change: it is a point where an industry's products become too expensive and its resources exhausted, and where the coalitions that have held up that particular value model disintegrate. In other words, it is the point where an industry collapses under its own greed, of having captured too much value for itself, leaving too little to the other actors in the system.Peak Pharma argues that the neoliberal pharmaceutical system is reaching its 'peak' in several vital respects - peak pricing, peak concentration, peak financialization, and peak expansion. It uses the term to signal the crisis and possible end of an era-defining business model in the pharmaceutical sector. The book presents a synthesis of the authors' decade-long empirical investigations into social movements contesting the pharmaceutical market. It brings together a large body of knowledge that is currently spread across political economy, sociology, STS, organization studies, and the history of medicine, to follow the neoliberal dynamics that have engendered an acceleration toward 'peak' over the span of the last 40 years. It traces the emergence of different voices and groups that have contested this evolution, particularly around specific crisis points and revelatory moments, including the fight for access to HIV/AIDS medicines, the global health era, pharmaceutical corporate social responsibility, the advent of personalized medicine and digital health, Covid-19, and others. The authors trace the shifting coalitions between the pharmaceutical industry, patient organisations, and governments that kept propping up the neoliberal value system throughout this evolution. They show that the recent acceleration toward peak has led many centrist voices from patient organizations, academia and politics to start changing course from market repair to imagining alternative pharmaceutical economies, prominently including imaginaries around the pharmaceutical commons. The book closes with a set of recommendations for policy makers and civil society actors interested in fostering an alternative political economy of health.This is an open access title available under the terms of a [CC BY-NC-ND 4.0 International] licence. It is free to read at Oxford Scholarship Online and offered as a free PDF download from OUP and selected open access locations.…

Zustand: New.

Zustand: New. In English.

Zustand: New.

Zustand: New.